Bioptix, Inc., through its subsidiary, BiOptix Diagnostics, Inc., develops enhanced surface plasmon resonance technology platform for the detection of molecular interactions. The company also focuses on animal healthcare and owns important intellectual property rights related to veterinary products. In addition, it has granted a license relating to single chain reproductive hormone technology for use in no-human mammals, which is under active development by the licensee bovine rFSH. The company was formerly known as Venaxis, Inc. and changed its name to Bioptix, Inc. in November 2016. Bioptix, Inc. was founded in 2000 and is based in Castle Rock, Colorado.
This was that biotech that stuck "blockchain" in the name, which shockingly, should not increase your market cap 400%
Riot Blockchain shares plummet; CEO fires back at CNBC (Video) https://www.bizjournals.com/denver/...mmet-33-percent-ceo.html?ana=yahoo&yptr=yahoo
QuarkChain, Oath, Ink Blockchain Partnership Deal – As the use of blockchain technology becomes prevalent, it is becoming important for measures of dispute resolution and governance to be dynamic. The security of transactions over the blockchain platform has also become a critical issue that needs to be constantly monitored and addressed. QuarkChain and Oath Protocol Partnership. In light of this, QuarkChain and Oath Protocol have decided to bring their capital and manpower together in a joint venture that will see a tectonic shift in the manner in which the scalability and security in the blockchain industry will be dealt with. QuarkChain is an innovative public blockchain platform that provides a blockchain architecture that requires absolutely no permissions, aimed at achieving commercial standards on a global level. At the core it seeks to provide blockchain solutions that meet the present security needs of the market and that are appropriately decentralized.
